Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga

Indoco Remedies Limited (Indoco) announced today that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga, following a successful Inspection of the said facility from 15th September, 2025 to 19th September, 2025.

Ms. Aditi Panandikar, Managing Director, Indoco said, "We are pleased to have received the EIR from the USFDA for our API manufacturing facility located at Patalganga. This further reinforces our commitment to upholding the highest standards of quality and compliance, delivering trusted healthcare solutions to patients worldwide."

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 239.40 as compared to the previous close of Rs. 237.55. The total number of shares traded during the day was 1190 in over 132 trades.

The stock hit an intraday high of Rs. 239.50 and intraday low of 236.05. The net turnover during the day was Rs. 283679.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 Pharmaceuticals EIR USFDA APIManufacturingFacility Patalganga